Physician profile
Constance Smith
NPI 1760462584
$1,750.09
in general payments reported to CMS, 2019-2025
11 companies · $342 in 2025
The $342 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $49.32 · 2020: $169 · 2021: $150 · 2022: $247 · 2023: $542 · 2024: $250 · 2025: $342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,134.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $406.54 | 2022-2025 | Lumigan, Alphagan P, Vuity |
| Bausch & Lomb Americas INC. | $401.11 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Allergan, INC. | $275.81 | 2019-2022 | |
| Alcon Vision LLC | $210.25 | 2022-2025 | Clareon, Argos |
| Biotissue Holdings INC. | $155.85 | 2021-2025 | |
| Boston Scientific Corporation | $102.77 | 2023 | |
| Novartis Pharmaceuticals Corporation | $75.31 | 2020-2023 | |
| Ocular Therapeutix, INC. | $60.09 | 2023-2024 | Dextenza |
| Sun Pharmaceutical Industries INC. | $24.55 | 2021 | |
| Oyster Point Pharma, INC. | $24.17 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Constance Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.